Jaguar Health, Inc. filed with the Securities and Exchange Commission a definitive proxy statement in connection with the Company’s special meeting of…
Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 8, 2026, Jaguar Health, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement (the “Proxy Statement”) in connection with the Company’s special meeting of stockholders, to be held on Novem
How this was made
The 30-second read
Why it matters
The share reserve adjustment could dilute existing shareholders, influencing short‑term price action ahead of the special meeting.
Market read
Primary corporate action filing with modest market relevance for the stock and sector.
What to watch
The amendment also aligns the plan with the recent Series R preferred stock conversion, potentially improving capital structure.
Background
Jaguar Health filed a definitive proxy statement and supplemental disclosure regarding Proposal 3 to amend its 2014 Stock Incentive Plan.
Ticker impact
SEC 8‑K filing discloses a share reserve adjustment that could dilute existing shareholders if approved at the Nov 6 special meeting.
likely downward pressure as market prices in possible dilution
The filing reveals a six‑fold increase in shares available for issuance, which may be viewed unfavorably by investors.
Market effects
May affect other biotech micro‑caps as investors reassess dilution risk in similar incentive plans.
Limited to U.S. over‑the‑counter biotech segment.
Minimal global impact.
Counterpoint
If the increased share reserve enables stronger employee retention, it could support long‑term growth and offset dilution concerns.
Key entities
- companyJaguar Health, Inc.
Biotech firm filing the proxy statement.
